Ambrose Alli University attains research breakthrough in diabetes, cancer drug

Edo state’s Ambrose Alli University, Ekpoma, has achieved a significant breakthrough in its research and academic endeavours.

The institution has received authorization for the production and patents of GLUCOZIL, a product designed for treating diabetes mellitus.

Dr. Jonathan Emeka Emordi, Sub-Dean of Basic Clinical Sciences in the College of Medicine, stated that the National Agency for Food and Drug Administration and Control (NAFDAC) has granted approval for both production and usage of GLUCOZIL.

The product, as described by Emordi, is a natural remedy capable of regenerating damaged beta cells.

Its potential for long-term use could not only manage but even cure diabetes. Additionally, GLUCOZIL offers clinical benefits for treating an enlarged prostate, potentially negating the need for surgery.

• Ambrose Alli’s certificate to produce herbal drug for diabetes has expired — NAFDAC
• Breakthrough in Artificial Kidney Could End Dialysis
• Prostate Cancer Poses Increasing Risks to Men Above 40, Prompts Heightened Awareness – Experts
• NAFDAC Warns Against Consumption of Fruits Ripened with Calcium Carbide
• PhD Student (m/f/d) Cellular Parasitology
• Top Universities in Nigeria: Covenant, UI, FUTA Lead the Way

According to Emordi, the product has undergone rigorous scientific testing, confirming its correct dosage, safety for humans and animals, and its ability to cleanse the human system.

Acting Vice Chancellor Prof. Asomwan Sonnie Adagbonyin expressed pride in the university’s scholars for their determination to excel despite challenges.